['gastroparesis']
['velusetrag', 'placebo']

        Inclusion Criteria:

          -  Symptoms of gastroparesis (eg, nausea, early satiety, fullness, bloating, upper
             abdominal pain, retching or vomiting) for at least 3 months prior to Screening

          -  Composite score ≥2and <5 on nausea, bloating, feeling excessively full after meals,
             and not able to finish a normal-sized meal items (on the GCSI-2W) at Screening

          -  Delayed gastric emptying by either GES (gastric emptying scintigraphy) or GEBT(gastric
             emptying breath test)

          -  Upper gastrointestinal obstruction ruled out by endoscopy or other imaging (eg,
             computed tomography) after the onset of gastroparesis symptoms

          -  Willing to abstain from prohibited medications, including but not limited to,
             anticholinergics, acetylcholinesterase antagonists, or promotility medications (eg,
             metoclopramide, domperidone, prucalopride, erythromycin) for: 24 hours prior to
             gastric emptying test during Screening, if applicable; 24 hours prior to start of the
             Baseline period; and during the Baseline Period

          -  GCSI-24H 7-day mean composite score ≥2.5 and <5 at Day 1

        Exclusion Criteria:

          -  If Type 1 or Type 2 diabetic, a glycosylated hemoglobin (HbA1c) level >11%

          -  Prior history of gastric surgery, including but not limited to gastrectomy, gastric
             bypass, gastric banding, pyloroplasty, vagotomy, or fundoplication, which has
             manipulated the natural anatomy of the stomach

          -  History of intrapyloric botulinum toxin injection within 3 months of Screening or
             currently has functioning implantable electric stimulator

          -  History of alcohol or drug abuse or dependence within the last year prior to Screening
      